An evaluation of Echinacea angustifolia in experimental rhinovirus infections

Karl-Franzens-Universität Graz, Gratz, Styria, Austria
New England Journal of Medicine (Impact Factor: 54.42). 08/2005; 353(4):341-8. DOI: 10.1056/NEJMoa044441
Source: PubMed

ABSTRACT Echinacea has been widely used as an herbal remedy for the common cold, but efficacy studies have produced conflicting results, and there are a variety of echinacea products on the market with different phytochemical compositions. We evaluated the effect of chemically defined extracts from Echinacea angustifolia roots on rhinovirus infection.
Three preparations of echinacea, with distinct phytochemical profiles, were produced by extraction from E. angustifolia roots with supercritical carbon dioxide, 60 percent ethanol, or 20 percent ethanol. A total of 437 volunteers were randomly assigned to receive either prophylaxis (beginning seven days before the virus challenge) or treatment (beginning at the time of the challenge) either with one of these preparations or with placebo. The results for 399 volunteers who were challenged with rhinovirus type 39 and observed in a sequestered setting for five days were included in the data analysis.
There were no statistically significant effects of the three echinacea extracts on rates of infection or severity of symptoms. Similarly, there were no significant effects of treatment on the volume of nasal secretions, on polymorphonuclear leukocyte or interleukin-8 concentrations in nasal-lavage specimens, or on quantitative-virus titer.
The results of this study indicate that extracts of E. angustifolia root, either alone or in combination, do not have clinically significant effects on infection with a rhinovirus or on the clinical illness that results from it.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Echinacea extracts have been applied for immunostimulation for many years. The clinical application though is based mainly on delivered practical experiences rather than on the results of clinical studies. Since the cell-mediated immune response is controlled by a variety of soluble cytokines, the measurement of these substances may be a means for determining the cellular immunological potential. The current report focuses on the measurement of ex vivo cytokine production of patients treated orally with an aqueous extract from Echinacea purpurea in order to evaluate the alteration of immunological parameters during the treatment. 115 patients aged between 32 and 73 years, were entered into the study after a curative treatment of breast cancer. These patients were randomised in three groups: Group I: no therapy (n=35), Group II: therapy with 8 ml Echinacea extract daily for 3 weeks (n=43) and Group III: therapy with 24 ml Echinacea extract daily for 3 weeks (n=37). From all patients heparinized blood was taken at days 0, 14 and 21. For cell culture the blood was stimulated with PHA at 10 µg/ml or PWM at 5 µg/ml for 2 days. In the supernatants the levels of the cytokines IL1-alpha , IL2, IL6, IFN-gamma and TNF-alpha were determined by ELISA. Plasma levels of soluble cytokine receptors for IL2 and TNF were determined by ELISA. Measurement of the ex vivo leukocyte cytokine production in the blood cell cultures of the patients of Group II revealed a slight, yet not significant increase of IFN-gamma between day 1 and day 21 in comparison to the control group without treatment. In the blood cell cultures of the patients treated with 24 ml Echinacea extract daily a significant increase of IL1-alpha, IFN- gamma, TNF-alpha and TNF-p55 receptor could be observed between day 1 and day 21. From these results it can be concluded that orally applied Echinacea seems to have a dose-dependent immunostimulatory effect on monocytes and lymphocytes.
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is an association with acute viral infection of the respiratory tract and exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Although these exacerbations are associated with several types of viruses, human rhinoviruses (HRVs) are associated with the vast majority of disease exacerbations. Due to the lack of an animal species that is naturally permissive for HRVs to use as a facile model system, and the limitations associated with animal models of asthma and COPD, studies of controlled experimental infection of humans with HRVs have been used and conducted safely for decades. This review discusses how these experimental infection studies with HRVs have provided a means of understanding the pathophysiology underlying virus-induced exacerbations of asthma and COPD with the goal of developing agents for their prevention and treatment.
    Pulmonary Pharmacology &amp Therapeutics 11/2014; 30. DOI:10.1016/j.pupt.2014.10.005 · 2.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is difficult to experimentally infect volunteers with RV strains to which the subject demonstrates serological immunity. However, in RV challenges, viral clearance begins before de novo adaptive immune responses would develop. We speculated that adaptive immunity to RV reflects heterologous immunity by effector memory cells. DCs were generated from monocytes using GM-CSF and IL-4 and RV39 loading accomplished with a dose of ∼350 TCID50/105 cells. RV-induced maturation was established as modulation of MHC class II, CD80, CD83, and CD86. Circulating RV targeting CD4 and CD8 T cells were investigated as induction of RV-specific proliferation (CFSE-dilution). Maturation of DC by RV was confirmed as upregulation of MHC Class II (83.3±5.0% to 87.8±4.1%), CD80 (39.4±7.2% to 47.6±7.7%) and CD86 (78.4±4.7% to 84.1±3.4%). Both CD4 and CD8 memory T cells were recognized in the circulation of healthy subjects. RV drives DC maturation and results in their ability to present RV antigens to both T helper and cytotoxic lymphocytes. Both CD4 and CD8 cells capable of recognizing RV-associated antigens are present in the circulation of healthy subjects where they are presumably involved in immune surveillance and explain the rapid recruitment of an adaptive immune response during RV infection.
    PLoS ONE 01/2015; 10(1):e0115271. DOI:10.1371/journal.pone.0115271 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Jun 2, 2014